Novel Cannabis Extract NTI164 Improves Core Autism Symptoms

For families navigating autism spectrum disorder, treatment can sometimes feel like a search for ways to manage individual challenges rather than an option that addresses the broader picture. Medications are available for certain associated behaviors, while therapies and behavioral supports remain central to care. But what if a treatment could potentially influence several areas of functioning at once?

Emerging clinical research is giving researchers another reason to investigate that question. A standardized, low-THC, full-spectrum medicinal cannabis extract called NTI164 produced encouraging results in a randomized, placebo-controlled clinical trial involving children and adolescents with Level II and III autism. The findings are important, but perhaps most important is understanding exactly what they do and do not show. Let’s dive into the research and what it could mean for the future of autism care.

Why this Study Matters

Autism is a complex neurodevelopmental condition involving differences in social communication and interaction, along with restricted or repetitive behaviors and interests. Its presentation varies considerably from person to person, which makes developing medications for the condition particularly challenging.

In the United States, there are currently no medications specifically approved to treat the core features of autism. The FDA has approved risperidone and aripiprazole for irritability associated with autistic disorder, including behaviors such as aggression, self-injury, temper tantrums and rapidly changing moods. While medication that reduces severe irritability can be valuable, it is not the same as a treatment designed to improve areas such as adaptive functioning, social responsiveness, or repetitive behaviors. This is where the NTI164 research becomes particularly interesting.

What Is NTI164?

NTI164 is not simply a CBD oil or a cannabis product purchased from a dispensary. It is a standardized, proprietary full-spectrum medicinal cannabis formulation developed for clinical use. The extract contains predominantly CBDA, along with CBD, CBGA, CBDV, and other minor cannabinoids. It also contains very little THC, with previous descriptions of the formulation identifying THC at approximately 0.08%, well below 0.3%.

That formulation is important when interpreting the results, as the study does not establish that an ordinary CBD product, hemp-derived CBD supplement, or recreational cannabis product would produce the same effects. Those products can differ substantially in cannabinoid concentrations, purity, manufacturing standards and consistency. NTI164 was also administered as an investigational medicinal product under controlled clinical conditions.

What Did the Autism Study Examine?

The Harmony study was designed as a double-blind, randomized, placebo-controlled clinical trial. Participants with Level II or III autism were recruited through a tertiary pediatric neurology clinic and received either NTI164 or placebo during an eight-week blinded treatment period.

The investigational treatment was administered at doses of up to 20 mg/kg per day. Participants who initially received placebo could subsequently enter an eight-week open-label phase and receive NTI164. Clinical assessments incorporated both clinician- and caregiver-rated measures.

They evaluated overall clinical severity, adaptive functioning, social responsiveness, and other emotional and behavioral features. The broader assessment included areas such as social cognition, repetitive behavior, anxiety, mood, and the impact of symptoms on family life. This broader approach is one of the most compelling aspects of the research.

The Results Went Beyond Irritability

After eight weeks, participants receiving NTI164 demonstrated statistically significant and clinically meaningful improvements compared with placebo in overall clinical severity, adaptive functioning, and social responsiveness. Improvements were also reported across associated areas, including social cognition, repetitive behavior, anxiety, and mood-related symptoms.

Adaptive functioning is particularly interesting because it relates to practical abilities involved in everyday life. Depending on the assessment, this can include areas such as communication, socialization, and daily living skills. For families, changes in these areas can have significance beyond what a traditional symptom score might capture.

The researchers also reported improvements in caregiver assessments of family experience and quality of life. Participants who moved from placebo to NTI164 during the open-label phase subsequently demonstrated improvements similar to those observed during the blinded portion of the study.

Why Full-Spectrum Cannabis Matters

One question researchers continue to investigate is whether cannabinoids may have different effects when they are delivered together rather than isolated into a single compound. Most public discussion surrounding cannabis and autism has focused heavily on CBD, but NTI164 is designed as a full-spectrum formulation containing multiple cannabinoids, creating the entourage effect.

This does not prove that the entourage effect explains the autism findings. It does, however, provide a scientific rationale for studying carefully standardized combinations of cannabinoids rather than assuming that isolated CBD tells the entire story. The distinction is crucial because consumers may understandably hear “cannabis extract” and assume the findings apply broadly to cannabis products, but unfortunately, they do not.

Safety Profile for Autism Patients

The Harmony trial also reported an excellent safety profile for NTI164 during the study period. That is an important finding when considering a potential treatment for children and adolescents. Demonstrating that a therapy can produce meaningful changes is only part of the development process; researchers must also establish that the treatment can be used safely and consistently.

The eight-week treatment period, however, remains relatively short. Longer studies involving larger and more diverse populations will be necessary to better understand long-term safety, durability of benefits, and which patients might respond best.

Why the Study Needs More Research

Despite the encouraging findings, this study should not be interpreted as proof that medicinal cannabis is an established treatment for autism. The trial was relatively small, conducted at a single clinical site and followed participants during an eight-week double-blind period. Autism itself is highly heterogeneous, meaning results from one group of participants may not necessarily apply to everyone with autism.

There is also an important difference between statistical significance and clinical significance. A statistically significant result indicates that an observed difference is unlikely to be explained by chance alone under the study’s statistical assumptions. It does not mean every participant improved, nor does it mean the treatment will work equally well for every person with autism. Those questions require larger, longer, and independently replicated trials.

A Promising Step for Autism Research

The significance of the Harmony study may ultimately be less about declaring a new autism treatment and more about expanding the questions researchers are willing to ask.

NTI164 produced improvements across multiple domains, including overall clinical severity, adaptive functioning, social responsiveness, and emotional or behavioral symptoms, rather than focusing solely on irritability. That makes the findings worth watching.

For now, NTI164 remains an investigational treatment, and the results should not be used as a reason to substitute consumer cannabis or CBD products for established autism care. But if larger clinical trials reproduce these findings, standardized cannabinoid-based medicines could eventually become part of a much broader conversation about how autism-related challenges are treated.

The next phase of research will determine whether the promising signal seen in this trial can withstand the much bigger test with larger populations, longer follow-up, and independent confirmation. And for an area of medicine where treatments have traditionally focused heavily on associated behaviors rather than core autism-related challenges, that is a development worth paying attention to.

References:

^{1. Brooke A. Keating, Yelda Ogru, Esra Isikgel, Kanan Sharma, Dima El-Sukkari, Michael C. Fahey, NTI164, a novel medicinal cannabis extract, improves core symptoms of autism spectrum disorder: Results from a double-blind, randomised, controlled trial (The Harmony study), Neurotherapeutics, Volume 23, Issue 5, 2026, e01033, ISSN 1878-7479, https://doi.org/10.1016/j.neurot.2026.e01033}